An FDA panel has endorsed a multi cancer blood test. Here is what the evidence shows, where Australia stands, and why sensitivity and specificity matter.
A single blood test that screens for more than 50 types of cancer has moved a step closer to US regulatory approval, after an independent FDA advisory committee voted in favour of the GRAIL multi cancer early detection test. It is a genuine advance in the technology of early detection. It is also not a replacement for anything we already do, and it is not yet available in Australia. Both of those facts matter, and the gap between them is where good medicine lives.
Let me be precise about what this test is. It analyses cell free DNA, fragments of genetic material that tumours shed into the bloodstream. The test does not confirm cancer. It detects patterns in the blood that are consistent with cancer, and flags whether a signal is present. That distinction is the whole story, because everything that follows, the good and the difficult, flows from it.
What the evidence actually shows
The test detects signals across more than 50 cancer types, including several we currently have no routine screening pathway for, such as pancreatic and stomach cancer. That is the promise. Cancers found early are generally easier to treat, and for some tumour types early detection is the single biggest lever we have.
The evidence is also clear about the limits. This is a screening test, not a diagnostic one. A positive result means further investigation is needed, not that cancer is present. A negative result does not rule cancer out. The test has a low false positive rate, which is a real strength, but low is not zero, and at population scale even a small false positive rate generates a large number of people who need follow up.
That follow up is not trivial. Working up every positive result means imaging, specialist referrals, and in some cases procedures. The healthcare system burden is a legitimate concern, and it is one of the reasons regulators move carefully. A test that finds more cancers but overwhelms the system that has to investigate them does not automatically improve outcomes.
Cost is the other practical barrier. In the US the test is priced above $900, and it is currently available by prescription for people aged 50 and older. FDA approval could change access and insurance reimbursement. A final decision is expected by the end of the year.
Is the Galleri test available in Australia?
No. The Galleri test is not currently available in Australia, and it is early days yet. There is no TGA approval for it as a population screening tool, and no Medicare pathway. If you see it offered locally, treat that with caution.
This is not a criticism of the technology. It is how regulation should work. Australia's screening programs, bowel, breast, and cervical, are built on decades of evidence showing that the benefits outweigh the harms at a population level. A new test has to earn that same standard before it is rolled out, and that takes time, data, and independent review.
What I would say to patients who ask is this: the science is moving quickly, and that is genuinely exciting. But exciting and ready are different things. Whether a test like this becomes part of Australian practice, and for whom, is a question for regulators and for the evidence, not for marketing.
Sensitivity, specificity, and why they decide everything
These two words do most of the work in screening, and they are worth understanding in plain terms.
Sensitivity is how good a test is at finding what it is looking for. A highly sensitive test catches most people who have the condition. A test with low sensitivity misses cases, which is called a false negative.
Specificity is how good a test is at correctly clearing people who do not have the condition. A highly specific test rarely flags someone who is well. A test with low specificity produces false positives, which means healthy people get flagged and then need investigation.
No test is perfect at both. There is usually a trade off, and where a test sits on that trade off determines how it should be used.
There is a third factor that matters just as much, and it is the one most people have never heard of: pre test probability. This is simply how likely it is that a given person has the condition before the test is done. It depends on age, symptoms, family history, and risk factors.
Why does it matter? Because the same test performs very differently depending on who you give it to. In a high risk group, a positive result is more likely to be a true positive. In a low risk group, even a very good test produces a higher proportion of false positives. This is not a flaw in the test. It is mathematics, and it is why responsible use means matching the test to the person, not offering it to everyone indiscriminately.
Concept | Plain meaning | What goes wrong when it is poor |
|---|---|---|
Sensitivity | Finds people who have the condition | Missed cases (false negatives) |
Specificity | Correctly clears people who do not | Healthy people flagged (false positives) |
Pre test probability | How likely the condition is before testing | Misuse across risk groups, skewed results |
Good healthcare uses all three together. A test is a tool, not an answer.
The upstream shift in longevity medicine
There is a broader change happening in medicine, and this test sits inside it. For most of the last century, medicine waited for disease to announce itself and then treated it. The shift now is upstream: finding the earliest signals of trouble before symptoms appear, when intervention is most effective.
That is the logic behind the diagnostics I use every day. VO2 max tells us about cardiorespiratory fitness, one of the strongest predictors of all cause mortality in large cohort studies. DEXA shows body composition in a way BMI cannot. Blood biomarkers for lipids, glucose, HbA1c, inflammatory markers, and ApoB give us a picture of metabolic and cardiovascular risk years before an event. None of these are cancer tests, but they share the same philosophy: measure early, act on what is modifiable.
Multi cancer blood tests extend that philosophy into oncology. The appeal is obvious. The caution is equally obvious, because early detection only helps if the finding is actionable and the follow up is sound. Finding a signal you cannot act on, or acting on a signal that turns out to be noise, both cause harm.
This is where the three filters I use for any new technology apply. Evidence: what does the data actually show, and in whom? Safety: what are the downsides of a positive or negative result? Upside: does acting on this change the outcome for the patient in front of me? A test that passes all three earns its place. One that does not stays experimental, clearly framed, and supervised.
Innovation in longevity medicine is real, and it is accelerating. The discipline is in knowing which innovations are ready to use, which are promising, and which are still experimental. That is the honest middle, and it is where patients get the most value.
What this means for you
If you are in Australia, the practical position today is unchanged. The multi cancer blood test is not available here, and the national screening programs for bowel, breast, cervical and now lung cancer remain the evidence based foundation. If you are over 50, being up to date with bowel, breast and cervical screening matters, because these programs are proven to reduce deaths. If you are aged 50 to 70 with a significant smoking history, whether you still smoke or quit within the last 10 years, you may also be eligible for free lung cancer screening every two years through the national program that began in July 2025.
If you are travelling or have access to the test overseas, the responsible approach is to discuss it with a clinician who understands your risk profile. Whether a test like this is appropriate for you, and what a result would mean in your context, is discussed in consultation. It is not a decision to make from a headline.
The bigger picture is encouraging. We are getting better at finding disease earlier, and the tools are improving. But better tools still need good judgement about who to use them on, and that judgement is what a clinician brings. More years thriving, fewer years declining, is the goal. Getting there means using the evidence we have, and being honest about the evidence we do not yet have.
If you want to understand your own risk profile and what screening is appropriate for you, an initial consultation is the starting point. What it involves is discussed when you book.
General information, not individual medical advice. Speak to your own doctor.
FAQ
Is the Galleri test available in Australia? No. It is not currently available in Australia and has no TGA approval or Medicare pathway. It is early days yet, and any local offering should be treated with caution.
Does a positive multi cancer blood test mean I have cancer? No. It means a signal consistent with cancer was detected and further investigation is needed. The test does not confirm cancer.
What is the difference between sensitivity and specificity? Sensitivity is how well a test finds people who have the condition. Specificity is how well it clears people who do not. Both matter, and so does how likely the condition is before testing.
Should I get a multi cancer blood test instead of standard screening? No. It is designed as an adjunct to existing screening, not a replacement. Standard screening programs remain the evidence based foundation.
